The Franz diffusion cell transdermal absorption test is the internationally recognized in vitro method for evaluating how drugs, cosmetic ingredients, and chemicals permeate through human or animal skin. Conducted in accordance with OECD Test Guideline 428 and SCCS notes of guidance, this test provides critical permeation parameters such as flux, permeability coefficient, and dermal absorption percentage. This article explains the working principle, sample types, test items, experimental procedures, and regulatory applications of Franz cell permeation testing to support pharmaceutical development, cosmetic safety assessment, and chemical risk evaluation.
The Franz diffusion cell transdermal absorption test is a laboratory-based in vitro permeation technique used to quantify the rate and extent to which substances cross the skin barrier. Widely adopted by accredited third-party laboratories and research institutions, it serves as a scientifically validated bridge between formulation screening and human exposure assessment.
Technical Overview
The Franz diffusion cell, also known as the vertical diffusion cell (VDC), was introduced by Thomas J. Franz in 1975 and has since become the gold-standard apparatus for in vitro percutaneous absorption studies. The system consists of a donor compartment positioned above a skin membrane, a receptor compartment filled with receptor fluid beneath the membrane, a water-jacketed thermostat that maintains physiological temperature, a magnetic stirring system, and a sampling port for periodic fluid withdrawal.
The test is governed by Fick's law of diffusion: the test formulation is applied to the stratum corneum surface of the membrane, and the active substance diffuses down a concentration gradient into the receptor fluid. The receptor compartment is held at approximately 32 °C to mimic the surface temperature of human skin, while continuous stirring eliminates stagnant boundary layers and ensures uniform drug distribution. Samples are withdrawn at predetermined time points and analyzed to construct a permeation profile.
The method is supported by an established international regulatory and standards framework, including:
- OECD Test Guideline 428 (In Vitro Skin Absorption: Receptor Fluid Method)
- OECD Guidance Document No. 28 on the conduct of skin absorption studies
- SCCS Notes of Guidance for cosmetic ingredient safety evaluation
- USP General Chapter <1724> on performance tests for semisolid drug products
- FDA guidance documents on in vitro release testing (IVRT) and in vitro permeation testing (IVPT) for topical products
Testing Samples
Transdermal and Topical Pharmaceutical Products
Transdermal drug delivery systems (TDDS), patches, gels, creams, ointments, lotions, sprays, and solutions are routinely evaluated to characterize drug release and skin permeation behavior, compare formulation variants, and support formulation optimization.
Cosmetic and Personal Care Products
Leave-on products such as creams, lotions, serums, essences, and sunscreens, as well as rinse-off products including shampoos, body washes, and hair dyes, are tested to determine the dermal absorption of functional ingredients for margin-of-safety calculations required by cosmetic regulations.
Chemicals, Pesticides, and Novel Delivery Systems
Industrial chemicals subject to chemical registration programs, agricultural pesticides, household chemical products, and advanced carriers such as liposomes, ethosomes, transfersomes, polymeric nanoparticles, and dissolving or solid microneedle systems can all be assessed using the Franz cell platform.
Test Membranes
Biological membranes remain the preferred barrier model: excised human skin (typically from abdominoplasty or breast reduction surgery, obtained with informed consent), pig ear skin (the most widely accepted animal surrogate due to its physiological similarity to human skin), and rodent skin from hairless mice or rats. When biological tissue is unavailable, artificial membranes such as mixed cellulose ester, cellulose acetate, silicone sheets, or synthetic multilayer membranes may be used for screening or release studies.
Testing Items
A complete Franz cell study typically reports the following permeation parameters:
- Cumulative permeated amount (Q, in µg/cm²): the total quantity of test substance crossing the membrane per unit area over the study duration
- Steady-state flux (Jss, in µg/cm²/h): the slope of the linear portion of the cumulative permeation curve, representing the maximum permeation rate
- Apparent permeability coefficient (Kp, in cm/h): the steady-state flux normalized by the donor concentration, enabling comparison across substances
- Lag time (Tlag): the extrapolated time required to reach steady-state diffusion, reflecting partitioning into the membrane
- Dermal absorption percentage (% of applied dose): the fraction of the applied dose absorbed, obtained by summing receptor fluid content and skin tissue retention
- Skin retention (µg/g or % of dose): the amount remaining within the skin layers after the exposure period
- Mass balance recovery: the distribution of the applied dose among donor wash, skin tissue, tape strips, and receptor fluid, with an acceptable range typically between 85% and 115%
- In vitro release rate (for IVRT studies): characterization of formulation release kinetics independent of biological variability
Testing Methods
Membrane Preparation and Integrity Verification
Skin samples are carefully cleaned of subcutaneous fat and dermatomed to a defined thickness (commonly 200–500 µm for split-thickness or up to 1 mm for full-thickness skin), then equilibrated in the receptor fluid. Before dosing, membrane integrity is confirmed using validated techniques such as transepidermal water loss (TEWL) measurement, electrical resistance testing, or tritiated water permeability assessment. Damaged membranes are excluded from the study.
Receptor Medium and Test Conditions
The receptor fluid must dissolve the permeating substance freely while maintaining sink conditions, meaning its concentration in the receptor remains below approximately 10% of saturation solubility throughout the test. Phosphate-buffered saline (PBS, pH 7.4), normal saline, or PBS supplemented with bovine serum albumin, surfactants, or organic cosolvents are common choices. The water jacket is maintained at 32 ± 1 °C to reproduce skin surface temperature, and the receptor fluid (typically 5–12 mL per cell) is stirred continuously at 300–600 rpm.
Dose Application and Sampling
The test product is applied to the exposed diffusion area (commonly 0.6–5 cm²) at either a finite dose, which simulates realistic consumer exposure (typically 2–10 mg/cm² for semisolid formulations), or an infinite dose, which saturates the donor and enables steady-state parameter calculation. At predetermined intervals (for example, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours), aliquots of receptor fluid are withdrawn and immediately replaced with equal volumes of fresh pre-warmed medium to maintain constant volume. At study termination, the donor compartment is washed, the membrane is sectioned or tape-stripped, and all fractions are retained for mass balance analysis.
Analytical Quantification and Data Processing
Permeated concentrations are quantified using validated analytical methods, most commonly high-performance liquid chromatography (HPLC), LC-MS/MS, UV-visible spectrophotometry, or radiochemical detection. Cumulative permeation is corrected for sample removal, plotted against time, and subjected to linear regression to derive Jss, Kp, and lag time. Studies typically include at least four to six replicate cells, ideally using skin from multiple donors, with acceptance criteria documented before testing begins.
Applications
Franz cell transdermal absorption testing supports decision-making across multiple industries:
- Transdermal and topical drug development: screening candidate formulations, optimizing penetration enhancers, and demonstrating product performance for regulatory submissions
- Bioequivalence and biowaiver support: IVPT comparison of test and reference topical products under USP <1724> and FDA-recommended conditions
- Cosmetic safety assessment: converting dermal absorption data into systemic exposure dosage (SED) values for margin-of-safety calculations under SCCS and national cosmetic safety frameworks
- Chemical and pesticide risk assessment: generating absorption data for dermal exposure evaluations required under chemical registration and agrochemical review programs
- Novel delivery system research: evaluating microneedles, vesicular carriers, and nanoparticle systems for enhanced skin delivery or reduced systemic exposure
- Quality control: release-rate testing of transdermal patches and semisolid batches as a product performance indicator
FAQ
Why is pig ear skin so widely used?
Pig ear skin closely resembles human skin in thickness, lipid composition, follicle density, and permeability characteristics. It is ethically acceptable, readily available from food-industry sources, and formally recognized by OECD and SCCS guidance as a suitable surrogate when fresh human skin cannot be obtained.
How long does a typical test last?
A standard permeation study runs for 24 hours, consistent with OECD Test Guideline 428. Studies may be extended to 48 or 72 hours for slowly permeating substances or controlled-release formulations, provided membrane integrity is re-verified at the end of the exposure period.
What is the difference between finite and infinite dose applications?
A finite dose mimics real-world product usage and reflects depletion of the applied dose over time, making it suitable for safety-relevant exposure estimates. An infinite dose keeps the donor concentration effectively constant, enabling calculation of maximum steady-state flux and permeability coefficients under saturated thermodynamic conditions.
What are sink conditions and why do they matter?
Sink conditions mean the test substance remains freely soluble in the receptor fluid, with its concentration staying below about 10% of saturation solubility. This prevents back-diffusion and ensures the measured permeation rate reflects the skin barrier rather than receptor-side solubility limitations.
Can Franz cell results replace clinical or animal studies?
In vitro permeation data are accepted by major regulatory authorities for risk assessment and formulation comparison, and they significantly reduce animal testing in line with the 3Rs principle (replacement, reduction, refinement). However, they complement rather than fully replace in vivo studies, particularly where metabolism or systemic pharmacokinetics must be characterized.
Which organizations should conduct this testing?
Studies intended for regulatory submission should be performed by accredited third-party laboratories operating under GLP or ISO/IEC 17025 quality systems, with validated analytical methods, documented membrane sourcing, and full compliance with OECD TG 428 and applicable regional standards.
